Kids with certain PCSK9 gene changes keep having lower 'bad' cholesterol as they grow up—this finding is from the abstract summary - full study details were not available
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether pharmacologic PCSK9 inhibition from childhood produces similar lifelong LDL lowering as seen in natural mutation carriers.
A long-term, double-blind RCT in 500 children (ages 5–10) with familial hypercholesterolemia, randomized to PCSK9 inhibitor (e.g., evolocumab) vs placebo, followed for 20 years to assess cumulative LDL exposure and early atherosclerosis via carotid IMT, with genetic subgroup analysis.
The consistency and magnitude of lifelong LDL reduction associated with PCSK9 mutations across multiple cohort studies.
A meta-analysis of all longitudinal cohort studies tracking LDL cholesterol from childhood to adulthood in PCSK9 mutation carriers vs noncarriers, reporting mean differences and 95% CIs, with subgroup analysis by mutation type and race.
The natural history of LDL cholesterol in PCSK9 mutation carriers across decades.
A multi-generational cohort study following 2,000 individuals with known PCSK9 mutations from age 4 to 50, with annual lipid panels, cardiovascular imaging, and lifestyle tracking to assess long-term outcomes.